Mechanism

Evidence tier: 4 — Receptor-protein interaction characterized in vitro and in mouse models; downstream senescent-cell clearance demonstrated in animal models only.

FOXO4-DRI (also marketed as Proxofim) is a 47-amino-acid D-retro-inverso peptide designed to disrupt the protein-protein interaction between FOXO4 (Forkhead box O4) and p53 inside senescent cells. The D-retro-inverso construction — the peptide synthesized from D-amino acids in reversed sequence — is a stability hack: the molecule resists proteolytic degradation that would destroy the native L-amino-acid sequence, while retaining the three-dimensional binding geometry that engages FOXO4.

The mechanistic premise comes from the canonical animal-model paper, Baar 2017 in Cell (PMID 28340339). Senescent cells accumulate with age and contribute to age-related pathology via the senescence-associated secretory phenotype (SASP) — inflammatory cytokines, MMPs, and growth factors that damage neighboring tissue. Within senescent cells, FOXO4 binds p53 and prevents p53-mediated apoptosis, allowing the senescent cell to persist despite the molecular damage that would otherwise trigger programmed cell death.

FOXO4-DRI competitively displaces p53 from FOXO4. The released p53 relocalizes to the cytosol and mitochondria, triggering senescent-cell-specific apoptosis without affecting healthy cells (where the FOXO4-p53 interaction is not the rate-limiting apoptosis brake). In the Baar 2017 mouse work, FOXO4-DRI cleared senescent cells from aged mice, restored fitness markers, hair density, and renal function. Subsequent work has extended the mechanism to senescent chondrocytes, vascular endothelial cells, and Leydig cells in animal models.

The mechanism is conceptually clean and the in-vitro/in-mouse data is consistent. The translational unknowns are which senescent-cell populations matter most in humans, the dose-response relationship in human tissues, and whether 47-amino-acid peptide delivery achieves meaningful tissue concentrations at any tolerable systemic dose.

Typical protocols

Evidence tier: 5 — No human trials exist. Protocols circulating are animal-model-derived or fully community-evolved.

There are no published human clinical trials of FOXO4-DRI as of May 2026. Frame protocols accordingly: they describe what's circulating, not what's validated.

The animal-model dosing in Baar 2017 used intraperitoneal injection at 5 mg/kg three times per week for 2-3 weeks. Community-circulated protocols for human research-context use extrapolate from this with no validated translation — typical reported doses are 0.05-0.5 mg/kg subcutaneously, administered in short cycles (3-5 doses over 1-2 weeks) followed by extended washout periods on the rationale that senescent-cell clearance should require infrequent dosing rather than continuous treatment.

The honest assessment: there is no validated human dose, no validated dosing schedule, no validated cycling pattern, and no validated tissue-targeting strategy. Any specific number circulating in peptide-research communities is unsupported by clinical evidence. Patients considering FOXO4-DRI should treat this as a pre-clinical research molecule rather than a usable therapeutic.

Evidence by indication

Evidence tier: 3 — Animal-model evidence is reasonably extensive; human-RCT evidence is zero.

Senescent-cell clearance / general aging (Baar 2017, mouse): The original Cell paper (PMID 28340339) showed FOXO4-DRI cleared senescent cells from aged, fast-aging, and chemotherapy-aged mice, with restored fitness (running wheel performance), hair regrowth, and renal function. The effect was attributable specifically to senescent-cell apoptosis rather than off-target effects on healthy cells.

Osteoarthritis / chondrocyte senescence: In-vitro work has shown FOXO4-DRI selectively eliminates senescent chondrocytes from expanded human cartilage cells, supporting a hypothesis for OA therapy. No human OA RCT exists.

Vascular aging / endothelial senescence: Mouse work has demonstrated improved aortic function with FOXO4-DRI treatment of aged or accelerated-aging models.

Reproductive aging (Leydig cells): Mouse work has shown FOXO4-DRI restoration of testosterone production in aged mice via clearance of senescent Leydig cells.

Cancer (senescent cancer cells): Several in-vitro and in-vivo cancer-model studies have explored FOXO4-DRI for eliminating chemotherapy-induced senescent cancer cells, with mixed but promising results.

Human evidence: None. Cleara Biotech (later renamed) was formed to commercialize the academic FOXO4-DRI work. The company's clinical pipeline as of 2026 has not advanced to first-in-human dosing of FOXO4-DRI specifically. The alternative senolytic with the most human data is the dasatinib + quercetin combination (small-molecule senolytic cocktail) which has completed several open-label and early RCT human studies — see the FOXO4-DRI vs Dasatinib + Quercetin comparison. The plant-flavonoid fisetin is another small-molecule senolytic with thin human data — see FOXO4-DRI vs Fisetin.

Safety profile

Evidence tier: 4 — Mouse safety data; zero human safety characterization.

In Baar 2017, FOXO4-DRI was well-tolerated in mice over the dosed period with no evidence of acute toxicity at therapeutic doses. The mechanistic safety logic is favorable — selective senescent-cell apoptosis should not damage healthy tissue — but this has not been confirmed in any human dose-escalation study.

Theoretical concerns for human translation include:

1. Immune activation from senescent-cell apoptosis (release of intracellular contents in a wave of cell death could trigger inflammatory response — a "senolytic crisis" analogous to tumor-lysis syndrome) 2. Off-target effects in healthy tissues at higher doses where the FOXO4-p53 selectivity may break down 3. Cardiovascular and hepatic safety under sustained dosing, neither characterized in any model 4. Immunogenicity of a 47-aa synthetic peptide repeatedly administered 5. Sourcing and contamination — research-supplier material varies in purity, and FOXO4-DRI synthesis is not trivial

There is no characterized safety profile in humans. Patients considering this molecule should treat it as a pre-clinical research compound rather than a usable therapeutic.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning across the senolytic landscape.

The senolytic field as of 2026:

Dasatinib + Quercetin (small-molecule senolytic cocktail): Most human data, completed early trials in IPF, frailty, and Alzheimer's; modest effect sizes but real human dosing experience
Fisetin (plant flavonoid): Thin human data, ongoing trials in osteoarthritis and frailty; favorable safety profile but unproven efficacy
Navitoclax (BCL-2 inhibitor): Approved for oncologic use, repurposed senolytic in some studies; significant hematologic toxicity limits broader use
FOXO4-DRI: Best mechanistic specificity on paper, zero human data, pre-clinical only

FOXO4-DRI's theoretical advantage is selectivity — it targets a senescent-cell-specific protein interaction rather than broad-spectrum apoptosis-pathway modulation. Whether this theoretical selectivity translates to a clinical advantage over the small-molecule senolytics will not be known until first-in-human studies are conducted. As of 2026, the validated senolytic options for clinician consideration are dasatinib + quercetin and fisetin, not FOXO4-DRI.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

FOXO4-DRI is not FDA-approved for any indication, not on the FDA bulks list for 503A or 503B compounding, and is not lawfully available through US compounding pharmacy channels. ProxofIM is the trade name used by some research-supplier vendors. The molecule has not entered formal clinical development as of 2026 — there is no IND, no FDA orphan-drug or breakthrough-therapy designation, no Phase 1 trial. WADA does not list FOXO4-DRI specifically. Patients seeking access can do so only through research-supplier channels, with the full set of unregulated-peptide concerns (purity, contamination, dose accuracy) compounded by the fact that this molecule is more synthetically complex than most peptides and harder to produce at consistent quality. Discuss any senolytic intervention with a clinician familiar with the senescent-cell literature.

References

Baar MP, Brandt RMC, Putavet DA, et al. 2017. Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging. Cell. PMID 28340339
Blanchard J, Chohan MO, Li B, et al. 2010. Beneficial effect of a CNTF tetrapeptide on adult hippocampal neurogenesis, neuronal plasticity, and spatial memory in mice. J Alzheimers Dis. PMID 20952820 — cited as comparator for "preclinical-only peptide with no human RCT" framing.

Limitations

This page does not constitute medical advice. FOXO4-DRI sits in a pre-clinical research-context category, not the therapeutic category. There are no human RCTs, no characterized human dose-response, no characterized human safety profile, and no FDA-approved pathway. Patients pursuing FOXO4-DRI through research-supplier channels are operating outside any clinical evidence base, and the molecule should not be framed as a treatment for aging, age-related disease, or any specific indication. We would update our framing if Cleara Biotech (or its successor) initiates a Phase 1 trial, if any FOXO4-p53-targeting molecule reaches FDA review, or if rigorous human safety data emerges. The senolytic field as a whole is promising but immature; FOXO4-DRI is the least clinically developed of the leading senolytic candidates.

FOXO4-DRI